More than half of people diagnosed with advanced melanoma are now surviving the disease for 10 years or more.
Melanoma is a type of skin cancer.
Only one in 20 patients with advanced melanoma would survive for only five years, 15 years ago.
Drugs, Ipilimumab and nivolumab, are a type of targeted immunotherapy called an immune checkpoint inhibitor.
They work by helping the immune system find and destroy cancer cells as they spread.
A new study by The Royal Marsden in Sutton shows they have both helped prolong lives and in combination, the results were even better.
Over half of trial participants have survived more than 10 years.
Data also showed that, when taken alone, nivolumab had a melanoma-specific survival of 44%.
